Ionis Pharmaceuticals News

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67

Futu NewsDec 21 21:00 · Ratings

Ionis Pharmaceuticals' Growth Prospects Bolstered by FDA Approval of Tryngolza

TipRanksDec 21 02:13

Sector Update: Health Care Stocks Mixed Premarket Friday

MT NewswiresDec 20 22:04

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts

BenzingaDec 20 22:01

Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

BenzingaDec 20 20:18 · Ratings

Ionis Pharmaceuticals Analyst Ratings

BenzingaDec 20 20:16 · Ratings

Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug

MT NewswiresDec 20 17:36

The rare disease drug Olezarsen under Ionis Pharmaceuticals (IONS.US) has been approved by the FDA.

The FDA has approved Olezarsen, a product of Ionis Pharmaceuticals, for the treatment of familial chylomicronemia syndrome (FCS).

Zhitong FinanceDec 20 15:28

Trading Halt: Halt Status Updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times

BenzingaDec 20 07:55

Express News | Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End

BreakingsDec 20 07:29

TRYNGOLZA (Olezarsen) Approved in U.S. as First-ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet

PR NewswireDec 20 07:28

Trading Halt: Halted at 4:28:30 P.m. ET - Trading Halt: Halt News Pending

BenzingaDec 20 05:28

New Strategy? Cathie Wood's ARK Purchases Shares in Futu, Significantly Increased Its Stake in AI Healthcare Company Tempus AI and Sold Off Shopify

Cathie Wood's ARK ETF announced the daily Trade details for Tuesday, December 17, 2024.

Futu NewsDec 18 18:22

Worst Performing Stocks for Tax Loss Selling – Wolfe

Seeking AlphaDec 17 03:59

Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx

Seeking AlphaDec 14 04:00

Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com

BusinesswireDec 12 01:41

How Much Upside Is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

Zacks Dec 11 22:05

Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $75

Futu NewsDec 10 21:34 · Ratings

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Yahoo FinanceDec 7 00:31

Strong Week for Ionis Pharmaceuticals (NASDAQ:IONS) Shareholders Doesn't Alleviate Pain of Five-year Loss

Simply Wall StDec 6 03:19